Pfizer (PFIZER) | Financial Analysis & Statements
Pfizer Ltd. Large-cap Healthcare
TL;DR: Financial Overview - Revenue, Profits & Key Metrics
Latest Quarterly: Jun 2025Income Metrics
Revenue
6.0B
Gross Profit
3.9B
64.97%
Operating Income
2.0B
32.44%
Net Income
1.9B
31.80%
EPS (Diluted)
₹41.91
Balance Sheet Metrics
Total Assets
49.1B
Total Liabilities
6.9B
Shareholders Equity
42.2B
Debt to Equity
0.16
Cash Flow Metrics
Revenue & Profitability Trend
Quarter Income Flow
Jun 30, 2025
Annual Income Flow
2025
Pfizer Income Statement From 2021 to 2025
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Revenue | 22.8B | 21.9B | 24.2B | 26.1B | 22.4B |
| Cost of Goods Sold | 8.1B | 8.0B | 8.8B | 9.5B | 8.0B |
| Gross Profit | 14.7B | 14.0B | 15.5B | 16.6B | 14.4B |
| Gross Margin % | 64.4% | 63.7% | 63.9% | 63.7% | 64.3% |
| Operating Expenses | |||||
| Research & Development | - | - | - | - | - |
| Selling, General & Administrative | 2.0B | 2.6B | 2.4B | 2.8B | 2.4B |
| Other Operating Expenses | 1.5B | 1.5B | 1.6B | 4.2B | 1.2B |
| Total Operating Expenses | 3.5B | 4.1B | 4.0B | 7.0B | 3.6B |
| Operating Income | 6.8B | 5.8B | 7.1B | 7.2B | 6.1B |
| Operating Margin % | 29.9% | 26.3% | 29.3% | 27.6% | 27.2% |
| Non-Operating Items | |||||
| Interest Income | 1.6B | 1.7B | 854.9M | 489.4M | 387.4M |
| Interest Expense | 84.1M | 107.3M | 133.9M | 104.9M | 151.1M |
| Other Non-Operating Income | - | - | - | - | - |
| Pre-tax Income | 10.2B | 7.5B | 8.2B | 7.7B | 6.7B |
| Income Tax | 2.5B | 1.9B | 2.0B | 1.6B | 1.7B |
| Effective Tax Rate % | 24.5% | 26.1% | 24.3% | 20.7% | 25.6% |
| Net Income | 7.7B | 5.5B | 6.2B | 6.1B | 5.0B |
| Net Margin % | 33.7% | 25.1% | 25.8% | 23.5% | 22.2% |
| Key Metrics | |||||
| EBITDA | 9.1B | 8.1B | 9.1B | 9.0B | 7.9B |
| EPS (Basic) | ₹167.79 | ₹120.51 | ₹136.38 | ₹133.89 | ₹108.77 |
| EPS (Diluted) | ₹167.79 | ₹120.51 | ₹136.38 | ₹133.89 | ₹108.77 |
| Basic Shares Outstanding | 45747732 | 45750372 | 45750372 | 45750990 | 45750372 |
| Diluted Shares Outstanding | 45747732 | 45750372 | 45750372 | 45750990 | 45750372 |
Income Statement Trend
Join Our India Telegram Channel
Get Instant Market Updates: 52-Week High/Low Alerts, Breakout Notifications & Expert Stock Analysis Delivered To Your Phone. Join Traders Making Informed Decisions Daily!
Pfizer Balance Sheet From 2021 to 2025
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Assets | |||||
| Current Assets | |||||
| Cash & Equivalents | 5.0B | 1.1B | 366.0M | 627.6M | 1.6B |
| Short-term Investments | 22.9B | 19.1B | 18.0B | 15.5B | 9.4B |
| Accounts Receivable | 1.9B | 1.9B | 1.5B | 1.2B | 1.1B |
| Inventory | 4.8B | 4.3B | 4.2B | 4.5B | 4.4B |
| Other Current Assets | 9.4M | 9.5M | 5.0M | 17.1M | 1.5B |
| Total Current Assets | 35.1B | 27.7B | 25.3B | 24.0B | 19.1B |
| Non-Current Assets | |||||
| Property, Plant & Equipment | 1.7B | 1.5B | 1.8B | 0 | 1.9B |
| Goodwill | 10.8B | 10.9B | 11.0B | 11.5B | 12.0B |
| Intangible Assets | 243.1M | 342.7M | 442.3M | 945.5M | 1.4B |
| Long-term Investments | - | - | - | - | - |
| Other Non-Current Assets | 501.2M | 500.9M | 257.5M | 257.5M | 257.5M |
| Total Non-Current Assets | 14.0B | 14.6B | 14.8B | 15.0B | 13.6B |
| Total Assets | 49.1B | 42.3B | 40.0B | 39.0B | 32.7B |
| Liabilities | |||||
| Current Liabilities | |||||
| Accounts Payable | 1.5B | 1.7B | 2.2B | 2.6B | 2.8B |
| Short-term Debt | 407.8M | 401.9M | 411.5M | 392.5M | 632.3M |
| Current Portion of Long-term Debt | - | - | - | - | - |
| Other Current Liabilities | 609.6M | 938.5M | 708.8M | 2.3B | 2.2B |
| Total Current Liabilities | 5.7B | 5.5B | 6.6B | 8.5B | 7.7B |
| Non-Current Liabilities | |||||
| Long-term Debt | 676.2M | 543.5M | 933.2M | 1.3B | 426.8M |
| Deferred Tax Liabilities | - | - | - | - | - |
| Other Non-Current Liabilities | - | - | - | - | - |
| Total Non-Current Liabilities | 1.2B | 866.8M | 1.4B | 1.8B | 985.2M |
| Total Liabilities | 6.9B | 6.3B | 7.9B | 10.4B | 8.7B |
| Equity | |||||
| Common Stock | 457.5M | 457.5M | 457.5M | 457.5M | 457.5M |
| Retained Earnings | 24.4B | 18.3B | 14.6B | 11.3B | 6.8B |
| Treasury Stock | - | - | - | - | - |
| Other Equity | - | - | - | - | - |
| Total Shareholders Equity | 42.2B | 36.0B | 32.1B | 28.6B | 23.9B |
| Key Metrics | |||||
| Total Debt | 1.1B | 945.4M | 1.3B | 1.7B | 1.1B |
| Working Capital | 29.4B | 22.2B | 18.7B | 15.4B | 11.3B |
Balance Sheet Composition
Pfizer Cash Flow Statement From 2021 to 2025
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Operating Activities | |||||
| Net Income | 10.2B | 7.5B | 8.2B | 7.7B | 6.7B |
| Depreciation & Amortization | - | - | - | - | - |
| Stock-Based Compensation | 136.6M | 144.5M | 127.0M | 117.7M | 105.6M |
| Working Capital Changes | 405.1M | -1.5B | 556.3M | 480.1M | 92.5M |
| Operating Cash Flow | 9.1B | 4.5B | 8.1B | 7.9B | 6.6B |
| Investing Activities | |||||
| Capital Expenditures | 1.2B | 339.7M | -637.6M | -132.5M | -176.2M |
| Acquisitions | - | 0 | 1.8B | 0 | - |
| Investment Purchases | - | - | - | -6.1B | -5.0B |
| Investment Sales | - | - | - | - | - |
| Investing Cash Flow | 1.4B | 341.2M | 1.2B | -6.2B | -5.1B |
| Financing Activities | |||||
| Share Repurchases | - | - | - | - | - |
| Dividends Paid | -1.6B | -1.8B | -3.0B | -1.6B | -15.2B |
| Debt Issuance | - | - | - | - | - |
| Debt Repayment | - | - | - | - | - |
| Financing Cash Flow | -1.6B | -1.8B | -3.0B | -1.6B | -15.2B |
| Free Cash Flow | 6.3B | 2.4B | 2.9B | 6.5B | 4.1B |
| Net Change in Cash | 8.9B | 3.0B | 6.3B | 80.7M | -13.7B |
Cash Flow Trend
Pfizer Key Financial Ratios
Valuation Ratios
P/E Ratio (TTM)
25.56
Forward P/E
25.15
Price to Book
5.66
Price to Sales
8.78
PEG Ratio
2.28
Profitability Ratios
Profit Margin
34.39%
Operating Margin
33.17%
Return on Equity
18.20%
Return on Assets
15.63%
Financial Health
Current Ratio
5.38
Debt to Equity
2.33
Beta
0.17
Per Share Data
EPS (TTM)
₹186.40
Book Value per Share
₹841.24
Revenue per Share
₹542.66
Peer Financial Comparison
| Company | Market Cap | P/E Ratio | P/B Ratio | ROE | Profit Margin | Debt/Equity |
|---|---|---|---|---|---|---|
| PFIZER | 218.8B | 25.56 | 5.66 | 18.20% | 34.39% | 2.33 |
| GlaxoSmithKline | 422.7B | 41.55 | 24.80 | 47.54% | 26.86% | 2.09 |
| Sanofi Consumer | 105.9B | 43.91 | 27.44 | 73.09% | 27.33% | 6.46 |
| Marksans Pharma | 86.2B | 23.96 | 3.20 | 15.29% | 12.85% | 12.24 |
| Sanofi India Limited | 79.3B | 24.31 | 10.59 | 40.59% | 17.78% | 2.38 |
| Senores | 41.0B | 35.50 | 5.54 | 7.21% | 18.36% | 28.90 |
Financial data is updated regularly. All figures are in the company's reporting currency.




